1  is inhibited by FGF-1, heparan sulfate, and heparinoids.

2                                          The heparinoids also showed similar differences in their abi

3   Surprisingly, heparin, chemically modified heparinoids, and monoclonal antibodies to heparan sulfat

4 anticoagulation regimens, including heparin, heparinoids, antithrombins, or fibrinolytics (e.g., tiss

5            Low-molecular-weight heparins and heparinoids are superior to unfractionated heparin in th

6                           As a result, these heparinoids can control the alternative complement pathw

7 lly we showed that certain low anticoagulant heparinoids can inhibit properdin binding to tubular HS,

8 bitor (e.g., argatroban or lepirudin) or the heparinoid danaparoid (where available) reduces the risk

9  Stroke Treatment, a randomized trial of the heparinoid danaparoid, were analyzed to determine whethe

10 contrast, smaller oligomers or the synthetic heparinoid fondaparinux were not able to block the bindi

11 ed with unfractionated heparin, the modified heparinoids had inhibitory activity in this general orde

12 nteraction and clearly differ from properdin-heparinoid interaction.

13   Interaction of anti-thrombin III (AT) with heparinoids is studied using a mixture of oligoheparin m

14                                     In turn, heparinoid-like gemini disaccharides (4a and 4b) were pr

15                 Experimental work shows that heparinoids may have neuroprotective properties.

16 vides access to structural variants of small heparinoid oligomers as versatile building blocks for ge

17 t compared heparins (unfractionated heparin, heparinoids, or low-molecular-weight heparin) with aspir

18 n be manipulated with some low anticoagulant heparinoids, which can be important for preventing compl

19 w the creation of a variety of heparosan and heparinoids with utility for medical applications.